Inhibition of TRPC6 activity showed reduced glioma cell growth, G2 phase cell cycle arrest, and reduced growth of subcutaneously and intracranially implanted gliomas, as well as increased survival of mice in vivo (Ding et al., 2010). This evidence concerns the gene TRPC6 and central nervous system cancer.